196 related articles for article (PubMed ID: 30003374)
21. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
[TBL] [Abstract][Full Text] [Related]
22. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer.
Stock RG; Stone NN; Ianuzzi C; Unger P
Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):815-21. PubMed ID: 7591888
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
[TBL] [Abstract][Full Text] [Related]
24. No impact of blood transfusion on oncological outcome after radical prostatectomy in patients with prostate cancer.
Boehm K; Beyer B; Tennstedt P; Schiffmann J; Budaeus L; Haese A; Graefen M; Schlomm T; Heinzer H; Salomon G
World J Urol; 2015 Jun; 33(6):801-6. PubMed ID: 24989847
[TBL] [Abstract][Full Text] [Related]
25. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
McKay RR; Montgomery B; Xie W; Zhang Z; Bubley GJ; Lin DW; Preston MA; Trinh QD; Chang P; Wagner AA; Mostaghel EA; Kantoff PW; Nelson PS; Kibel AS; Taplin ME
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):364-372. PubMed ID: 29263420
[TBL] [Abstract][Full Text] [Related]
26. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
[TBL] [Abstract][Full Text] [Related]
27. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era.
Ung JO; Richie JP; Chen MH; Renshaw AA; D'Amico AV
Urology; 2002 Sep; 60(3):458-63. PubMed ID: 12350484
[TBL] [Abstract][Full Text] [Related]
28. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database.
Freedland SJ; Presti JC; Amling CL; Kane CJ; Aronson WJ; Dorey F; Terris MK;
Urology; 2003 Apr; 61(4):736-41. PubMed ID: 12670557
[TBL] [Abstract][Full Text] [Related]
29. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
Eggener SE; Roehl KA; Smith ND; Antenor JA; Han M; Catalona WJ
J Urol; 2005 Apr; 173(4):1150-5. PubMed ID: 15758725
[TBL] [Abstract][Full Text] [Related]
30. Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016).
Schmanke K; Okut H; Ablah E
Urology; 2021 Mar; 149():110-116. PubMed ID: 33227304
[TBL] [Abstract][Full Text] [Related]
31. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
32. Is More Always Better? An Assessment of the Impact of Lymph Node Yield on Outcome for Clinically Localized Prostate Cancer with Low/Intermediate Risk Pathology (pT2-3a/pN0) Managed with Prostatectomy Alone.
Seyedin SN; Mitchell DL; Mott SL; Russo JK; Tracy CR; Snow AN; Parkhurst JR; Smith MC; Buatti JM; Watkins JM
Pathol Oncol Res; 2019 Jan; 25(1):209-215. PubMed ID: 29079967
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.
Pound CR; Partin AW; Epstein JI; Walsh PC
Urol Clin North Am; 1997 May; 24(2):395-406. PubMed ID: 9126237
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the Walz Nomogram and Presence of Secondary Circulating Prostate Cells for Predicting Early Biochemical Failure after Radical Prostatectomy for Prostate Cancer in Chilean Men.
Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
Asian Pac J Cancer Prev; 2015; 16(16):7123-7. PubMed ID: 26514500
[TBL] [Abstract][Full Text] [Related]
35. Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.
Wilczak W; Wittmer C; Clauditz T; Minner S; Steurer S; Büscheck F; Krech T; Lennartz M; Harms L; Leleu D; Ahrens M; Ingwerth S; Günther CT; Koop C; Simon R; Jacobsen F; Tsourlakis MC; Chirico V; Höflmayer D; Vettorazzi E; Haese A; Steuber T; Salomon G; Michl U; Budäus L; Tilki D; Thederan I; Fraune C; Göbel C; Henrich MC; Juhnke M; Möller K; Bawahab AA; Uhlig R; Adam M; Weidemann S; Beyer B; Huland H; Graefen M; Sauter G; Schlomm T
Eur Urol; 2018 Sep; 74(3):376-386. PubMed ID: 29908878
[TBL] [Abstract][Full Text] [Related]
36. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
37. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
38. Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance.
Hong SK; Sternberg IA; Keren Paz GE; Kim PH; Touijer KA; Scardino PT; Eastham JA
Eur Urol; 2014 Aug; 66(2):214-9. PubMed ID: 23954083
[TBL] [Abstract][Full Text] [Related]
39. Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer.
Mahal BA; Aizer AA; Efstathiou JA; Nguyen PL
Cancer; 2016 Jan; 122(1):78-83. PubMed ID: 26371600
[TBL] [Abstract][Full Text] [Related]
40. Predictive factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins.
Aoun F; Albisinni S; Henriet B; Tombal B; Van Velthoven R; Roumeguère T
Scand J Urol; 2017 Feb; 51(1):20-26. PubMed ID: 27910728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]